Prostate Zn 21 concentrations are among the highest in the body, and a marked decrease in the level of this ion is observed in prostate cancer. Extracellular Zn 21 is known to regulate cell survival and proliferation in numerous tissues. In spite of this, a signaling role for extracellular Zn 21 in prostate cancer has not been established. In the present study, we demonstrate that prostate metastatic cells are impermeable to Zn 21 , but extracellular Zn 21 triggers a metabotropic Ca 21 rise that is also apparent in the presence of citrate. Employing fluorescent imaging, we measured this activity in androgen-insensitive metastatic human cell lines, PC-3 and DU-145, and in mouse prostate tumor TRAMP-1 cells but not in androgen-sensitive LNCaP cells. The Ca 21 response was inhibited by Gaq and phospholipase C (PLC) inhibitors as well as by intracellular Ca 21 store depletion, indicating that it is mediated by a Gq-coupled receptor that activates the inositol phosphate (IP 3 ) pathway consistent with the previously identified zinc-sensing receptor (ZnR). Zn 21 -dependent extracellular signal-regulated kinase and AKT activation, as well as enhanced Zn 21 -dependent cell growth and survival, were observed in PC-3 cells that exhibit ZnR activity, but not in a ZnR activitydeficient PC-3 subline. Interestingly, application of Zn 21 -citrate (Zn 21 Cit), at physiological concentrations, was followed by a profound functional desensitization of extracellular Zn 21 -dependent signaling and attenuation of Zn 21 -dependent cell growth. Our results indicate that extracellular Zn 21 and Zn 21 Cit, by triggering or desensitizing ZnR activity, distinctly regulate prostate cancer cell growth. Thus, therapeutic strategies based either on Zn 21 chelation or administration of Zn 21 Cit may be effective in attenuating prostate tumor growth.
Introduction
Zn 2þ homeostasis in the prostate is more dynamic than in other human tissues, as prostate cells accumulate this ion and secrete it into the prostatic and seminal fluid. Zn 2þ is secreted with citrate into the prostatic fluid (1) , where it is found at high, i.e. millimolar, concentrations (2) . The concentration of 'free Zn 2þ ' in this organ is, however, lower than these nominal values (3) since it is mostly complexed to citrate. The accumulation of Zn 2þ in prostate cells is facilitated by the activity of Zn 2þ transporters from the ZIP family, which mediate vectorial transport of this ion (4, 5) . By inhibiting mitochondrial aconitase, the major oxidizing enzyme of citrate, intracellular Zn 2þ contributes to citrate accumulation in the prostate cells that is then secreted into the seminal fluid (6, 7) . The inhibition of mitochondrial aconitase significantly lowers adenosine triphosphate (ATP) production, leading to bioenergetic deficiency and attenuation of nonneoplastic prostate cell growth (2) . It has been also shown that mitochondrial Zn 2þ accumulation is involved in the apoptotic pathways in prostate epithelial cells (8, 9) . Thus, intracellular Zn 2þ accumulation is expected to attenuate prostate cell growth.
That Zn 2þ plays a role in prostate tumorigenesis is implied by the fact that Zn 2þ -accumulating cells were found primarily in the dorsolateral lobe in a rat model, where prostate cancer is also most common in human (10, 11) . Furthermore, during prostate cancer development a 10-fold decrease in both Zn 2þ and citrate concentrations are observed in the prostate epithelium (2) . Decreased intracellular Zn 2þ has been associated with reduced expression of the Zn 2þ transporters, ZIP, that mediate influx of Zn 2þ into prostate epithelial cells (12) . It has been suggested that because of the lower Zn 2þ concentration in malignant cells, ATP production is more efficient than in the nonmalignant cells, thereby facilitating enhanced proliferation of the malignant cells. While metabolic and signaling roles for intracellular Zn 2þ have been suggested (2, 6, 13) , the possible contribution of extracellular Zn 2þ , or the Zn 2þ -citrate (Zn 2þ Cit) complex, to prostate cell growth is still unknown.
Extracellular Zn 2þ promotes cell growth by activating and regulating major signaling pathways in numerous cell types. Zn 2þ , for example, activates the mitogen-activated protein kinase (MAPK) pathway, leading to enhanced proliferation of the colonocytic tumor cell line, HT-29, and NIH3T3 fibroblasts (14) (15) (16) . Application of Zn 2þ also activates the phosphoinositide-3 kinase (PI3K) in human bronchial epithelial cells (17, 18) and leads to enhanced survival of fibroblasts (15, 19) and neurons (20) . Supplementation of Zn 2þ also reduces the cellular accumulation of the tumor suppressor p53 in breast cancer cells (21) .
Our previous work showed that extracellular Zn 2þ induces cellular signaling via a G-protein-coupled receptor (GPCR), termed zincsensing receptor (ZnR) (22) . We subsequently demonstrated Zn 2þ sensing activity in a variety of epithelial cells (14, 22, 23) with affinity in the 10-100 lM range, i.e. within the range of its physiological concentration in those tissues. ZnR triggers activation of the inositol phosphate (IP 3 ) pathway upon a rise in extracellular Zn 2þ . The subsequent Ca 2þ release in HT-29 colonocytes activates extracellular signal-regulated kinase (ERK) and PI3K pathways and enhances the activity of the Na þ /H þ exchanger, NHE1, which regulates cell volume and survival (14) . Desensitization of GPCRs is also a protective mechanism against prolonged and potentially harmful activation by their ligands. The ZnR is functionally desensitized following exposure to extracellular Zn 2þ (14, 23) . Desensitization of ZnR in HT-29 colonocytes abolished the Zn 2þ -dependent activation of the IP 3 and the MAPK pathways. Thus, ZnR is emerging as a major link between changes in extracellular Zn 2þ and signaling related to cell growth.
In the present study, we have examined the signaling role of extracellular Zn 2þ in prostate cancer cells. We demonstrate that a rise in extracellular Zn 2þ concentration induces ZnR activity and triggers signaling pathways that facilitate cell growth. Prolonged exposure to Zn 2þ subsequently desensitizes ZnR activity, suggesting that in normal prostate tissue, where Zn 2þ concentration is high, ZnR is inactive. Based on our data, we propose that in the neoplastic prostate and in peripheral tissues where metastatic cells encounter substantially lower Zn 2þ concentrations, ZnR is activated by transient increases in Zn 2þ concentration, thereby promoting prostate tumor cell growth.
supplemented with 10 mM (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) (HEPES), 1 mM sodium pyruvate, 10% fetal bovine serum, 4 mM L-glutamine and 0.5 lg/ml penicillin-streptomycin (24) . Cells were seeded on glass coverslips, one day prior to fluorescent imaging experiments.
Fluorescent calcium imaging
Cells grown on coverslips were loaded for 30 min at room temperature with 5 lM Fura-2 AM (TEF Labs, Austin, TX) in Ringer's solution (in millimolar): 120 NaCl, 5.4 KCl, 1.8 CaCl 2 , 0.8 MgCl 2 , 10 HEPES, 10 glucose, pH 7.4, containing 0.1% bovine serum albumin. Ca 2þ imaging was carried out as described previously (22) . The ratio of the fluorescent signal (R 5 F 340 /F 380 ) was normalized to an initial baseline averaged over first 10 points acquired (R b ) and presented as percentage of the baseline (R/R b Â 100). For Zn 2þ imaging, cells were loaded as described with 5 lM Newport Green and the fluorescent signal was monitored using 488 nm wavelength for excitation (25) . The fluorescent signal was normalized as described for Fura-2. In all experiments, representative graphs of 50-80 cells from at least three independent experiments are shown.
Immunoblot analysis
Cells were harvested immediately following treatment (unless otherwise indicated) into lysis buffer on ice in the presence of protease inhibitor mixture (Complete, Roche Applied Science, Mannheim, Germany) and centrifuged for 30 min (14 000 r.p.m.), as described previously (14) . Supernatants (cytosolic fraction) were collected, sodium dodecyl sulfate sample buffer was added and the samples were boiled for 5 min and then frozen at À80°C until used. Cell samples containing the cytosolic fraction (20 lg) were separated on 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis followed by immunoblotting. Antibodies against doubly phosphorylated ERK1/2 and total ERK1/2 or phosphorylated AKT and total AKT (Sigma Rehovot, Israel and Cell Signaling, Danvers, MA) were detected digitally using ChemImager 5 (Alpha-Innotech, Israel Labtrade), and blots were quantified using this software. Phospho-ERK1/2 or AKT levels were normalized to total ERK1/2 or AKT protein, respectively. Phosphorylation of ERK1/2 or AKT is presented as percentage of the effect triggered by application of 100 lM Zn 2þ unless otherwise indicated.
Cell proliferation assay
The quantitative sulphorhodamine B colorimetric assay (26) was used to determine cell proliferation. Cells (5000 cells per well) were seeded in 96-well plates. Cells were incubated daily (5 days) for 10 min in Ca 2þ -free Ringer's solution supplemented with 100 lM ZnSO 4 or with the Zn 2þ chelator calcium ethylenediamine tetra-acetic acid (CaEDTA) (100 lM). Cells were then reintroduced into RPMI medium containing 1% serum and CaEDTA. ZnR desensitization was induced by pretreating cells daily with 100 lM ZnSO 4 in Ca 2þ -containing Ringer's solution for 60 min followed by 3Â wash with Zn 2þ -free Ringer's solution. Cells were then stained with sulphorhodamine B and optical density was measured at 492 and 620 nm using enzyme-linked immunosorbent assay plate reader. Statistical analysis was performed on the averaged cell number (±SEM) of at least three independent experiments.
Cell viability assay Cells (70 000) were seeded in six-well plates. Cells treated with Zn 2þ , or controls, were centrifuged to sediment all cells to the bottom of the plate and trypan blue (0.4%, Sigma) was added (dilution 1:20) . Three images were acquired from each plate, using an upright Olympus microscope (Â10 objective) equipped with a SPOT digital camera. Cell counting was performed blind and averaged over three independent experiments.
Statistical analysis
Each bar graph represents an average ± SEM of at least three independent experiments. Statistical analysis was performed using paired Student's t-test, comparing each treatment to addition of Zn 2þ unless otherwise mentioned: Ã P , 0.05; ÃÃ P , 0.01.
Results
Since previous studies have shown a decrease in the expression of the ZIP transporters and intracellular Zn 2þ during prostate cancer (12), we sought to determine whether changes in Zn 2þ concentration activate cellular signaling. We first monitored Zn 2þ permeation rates in the androgen-insensitive, metastatic prostate cancer cell line, PC-3, using the intracellular Zn 2þ -specific dye, Newport Green. PC-3 cells loaded with Newport Green were monitored while superfusing the cells with Zn 2þ -containing Ringer's solution ( Figure 1A ). No increase in fluorescence was monitored when Zn 2þ (200 lM) was applied, whereas an increase in fluorescence was observed following addition of Zn 2þ (200 lM) in the presence of the Zn 2þ ionophore, pyrithione (5 lM). This indicates that PC-3 cells are highly impermeable to Zn 2þ and is in agreement with previous studies (2, 6, 12, 13) . We then asked if extracellular Zn 2þ induces intracellular Ca 2þ signaling. Changes in intracellular Ca 2þ triggered by Zn 2þ were monitored in PC-3 cells loaded with Fura-2. Application of 10-100 lM Zn 2þ was followed by a rise in fluorescence that was already apparent with the addition of 10 lM Zn 2þ and increased by 6-fold with 100 lM ( Figure 1B) . To determine if the Ca 2þ rise resulted from Ca 2þ influx from the extracellular medium or from Ca 2þ released from intracellular pools, PC-3 cells were superfused with Ca 2þ -containing or Ca 2þ -free Ringer's solution. The increase in fluorescence triggered by 100 lM Zn 2þ was independent of extracellular Ca 2þ ( Figure 1C ), indicating that it did not result from Ca 2þ permeation. To further study the role of the intracellular Ca 2þ stores, Zn 2þ was applied after depletion of intracellular Ca 2þ stores with the sarcoendoplasmic reticulum calcium ATPase inhibitor, thapsigargin (TG, 0.5 lM) and the purinergic P2Y agonist (uridine triphosphate, 100 lM) in Ca 2þ -free Ringer's solution. Following store depletion, when cytoplasmic Ca 2þ was at the basal level, application of Zn 2þ failed to elicit an increase in Fura-2 fluorescence ( Figure 1D ). This indicates that the observed rise in fluorescence is related to Ca 2þ release from TG-sensitive endoplasmic reticulum stores. Since Fura-2 is also a high affinity Zn 2þ probe (K d for Zn 2þ $2 nM), the lack of response following store depletion is a further proof that Zn 2þ does not permeate into the cells.
We next asked if the IP 3 pathway mediates the Zn 2þ -dependent Ca 2þ response in PC-3 cells, similar to the ZnR (22) . Application of the phospholipase C (PLC) inhibitor, U73122 (1 lM), was followed by inhibition of the Zn 2þ -dependent Ca 2þ response ( Figure 1E ). To assess the role of Gaq in linking Zn 2þ to activation of the IP 3 pathway, cells were incubated with a Gaq inhibitor, YM-254890 [1 lM (27)], and were subsequently superfused with Zn 2þ . The Zn 2þ -dependent Ca 2þ rise was completely inhibited by the application of YM-254890 ( Figure 1F ). Analysis of dose dependence of the Zn 2þ -dependent Ca 2þ response yielded a K 0.5 of 200 ± 35 lM for extracellular Zn 2þ (supplementary Figure 1 is available at Carcinogenesis Online), indicating that although the ZnR response is strongly activated by low 'free Zn 2þ ' concentrations found in the prostate, it is activated by a very broad range of Zn 2þ concentrations. Thus, our results strongly indicate that PC-3 cells possess a Gaq-coupled Zn 2þ sensing receptor that mediates activation of the IP 3 pathway to trigger intracellular Ca 2þ signaling. A similar Zn 2þ -dependent signaling pathway, triggered by a putative ZnR, was described previously by us (14, 22, 23) .
To determine if extracellular Zn 2þ -dependent signaling is also found in other prostate cancer cells, we studied Zn 2þ -dependent Ca 2þ release in the androgen-insensitive human prostate cancer cells, DU-145, and in TRAMP-1 cells, derived from mouse prostate tumor (28) . In DU-145 cells, application of 300 lM Zn 2þ triggered an intracellular Ca 2þ rise ( Figure 2A ). Yet, application of Zn 2þ (300 lM) following depletion of intracellular Ca 2þ stores, using ATP (100 lM) and TG (1 lM) in Ca 2þ -free Ringer's solution, failed to elicit an intracellular Ca 2þ rise. In TRAMP-1 cells, application of 100 lM Zn 2þ triggered an intracellular Ca 2þ rise ( Figure 2B ) that was diminished by the Gaq inhibitor, YM-254890 (1 lM). Finally, application of 100 lM (data not shown) or 300 lM Zn 2þ to the androgen-sensitive LNCaP, prostate cancer cell line ( Figure 2C ) did not trigger a Ca 2þ rise, although application of TG (1 lM) triggered a Ca 2þ rise, suggesting that Ca 2þ stores were not depleted. These results indicate that ZnR activity is triggered in the androgen-insensitive PC-3 and DU-145, as well as in TRAMP-1 cells, but not in the androgensensitive LNCaP cells.
Desensitization of Zn 2þ -dependent Ca 2þ signaling
We have previously demonstrated that the ZnR is prone to desensitization by prolonged exposure to Zn 2þ (14, 23) . We therefore asked if desensitization plays a role in Zn 2þ -dependent signaling also in prostate cells. To test this, PC-3 cells were treated with 100 lM Zn 2þ for 60 min in Ca 2þ -containing Ringer's solution, washed in Zn 2þ -free Ringer's (5 min) and subsequently Zn 2þ was reapplied while Extracellular zinc and zinc-citrate regulate growth and survival of prostate cancer cells monitoring intracellular Ca 2þ . Pretreatment with Zn 2þ resulted in complete inhibition of the Zn 2þ -dependent Ca 2þ response ( Figure  3A ), indicating that it is very effectively desensitized by Zn 2þ . In the prostate, Zn 2þ is present in very high concentrations (i.e. 6 mM), but is largely complexed with citrate (10 mM), which effectively lowers the concentration of free Zn 2 (3). It was of interest, therefore, to determine if Zn 2þ Cit, in this physiological milieu, modulates intracellular Ca 2þ signaling. We accomplished this by monitoring the Ca 2þ response of PC-3 cells following application of Zn 2þ Cit (6 mM Zn 2þ and 10 mM citrate). As shown in Figure 3B , no intracellular Ca 2þ rise was observed following application of Zn 2þ Cit at these concentrations. The free Zn 2þ concentration using this Zn 2þ Cit ratio is estimated to be 20 lM (WebMax software), a concentration that is potentially sufficient to trigger Zn 2þ -dependent signaling (see Figure 1B) . Modulating the concentrations of Zn 2þ and citrate, leading to a larger excess of free Zn 2þ , resulted in a smaller Ca 2þ response than that triggered by the same concentration of Zn 2þ alone ( Figure 3B and C) . This suggests that the Zn 2þ -dependent signaling was partially attenuated by Zn 2þ Cit. We then asked if Zn 2þ Cit, at physiological concentrations, will desensitize the Zn 2þ -dependent Ca 2þ response. The desensitization paradigm described for Zn 2þ was performed using Zn 2þ Cit at the physiological concentration (6 mM Zn 2þ and 10 mM citrate). Pre-exposure of PC-3 cells to Zn 2þ Cit was followed by profound attenuation of the Ca 2þ response to extracellular application of 100 lM Zn 2þ ( Figure 3D ). In contrast, when cells were preincubated with citrate (10 mM), in the absence of Zn 2þ , subsequent application of Zn 2þ triggered a robust Ca 2þ response, thereby attesting to a specific role for Zn 2þ Cit in desensitization of Zn 2þ -dependent signaling in PC-3 cells (see Discussion).
Role of Zn 2þ in activation of MAPK and PI3K in prostate cancer cells We then sought to determine whether in Zn 2þ -dependent PC-3 cells, extracellular Zn 2þ regulates the MAPK and PI3K pathways linked to proliferation and survival of prostate cancer cells (29) . Addition of 100 lM Zn 2þ for 10 min to PC-3 cells induced phosphorylation of both ERK1/2 and AKT, whereas control cells treated with the extracellular Zn 2þ chelator, CaEDTA (100 lM), exhibited very low phosphorylation ( Figure 4A and B) . No Zn 2þ permeation was observed in PC-3 cells, using this paradigm (see Figure 1A) , indicating that phosphorylation of ERK1/2 was trigged by extracellular Zn 2þ . We found that extracellular Zn 2þ triggered prolonged phosphorylation of both ERK1/2 and AKT, which lasted at least 3 h. Rates of Zn 2þ -dependent activation of ERK1/2 and AKT were different as maximal phosphorylation of ERK1/2 was apparent immediately after extracellular Zn 2þ application, whereas phosphorylation of AKT increased during the first 1.5 h period following application of Zn 2þ (100 lM).
We next addressed the role of the IP 3 pathway and possible cross talk between the MAPK and PI3K in mediating Zn 2þ -dependent signaling. Zn 2þ -dependent phosphorylation of ERK1/2 was completely blocked by the application of the MEK1/2 inhibitor, U0126 (1 lM), indicating that Zn 2þ -dependent ERK1/2 phosphorylation is mediated via MEK1/2 ( Figure 4C ). The application of the PI3K inhibitor, wortmannin (100 nM), inhibited the Zn 2þ -dependent AKT phosphorylation, indicating that it is mediated through the PI3K pathway ( Figure 4D ). Following application of the Gaq inhibitor, YM-254890 (1 lM, Figure 4C and D), Zn 2þ -dependent ERK1/2 and AKT phosphorylation was inhibited by 30 and 50%, respectively. This suggests that the IP 3 pathway is involved, but is not the sole pathway, in mediating Zn 2þ -dependent activation of ERK1/2 and AKT. Because protein kinase C (PKC) is activated by Ca 2þ and diacylglycerol (30) , both generated by the Zn 2þ -dependent signaling pathway, we asked if PKC is also participating in Zn 2þ -dependent activation of the MAPK and PI3K pathways (31) . The application of the PKC inhibitor bisindolylmaleimide (2 nM) attenuated ERK1/2 and AKT phosphorylation by $50%, suggesting that PKC activation is also partially mediating Zn 2þ -dependent activation of both pathways ( Figure 4C and D). Since cross talk between the MAPK and PI3K pathways was shown previously, we next examined whether their interaction affects Zn 2þ -dependent signaling in PC-3 cells. Application of the PI3K inhibitor, wortmannin (100 nM), attenuated ERK1/2 phosphorylation by $60%, whereas the MEK inhibitor, U0126 (1 lM), inhibited AKT phosphorylation by $50% (Figure 4C and D) . Finally, coapplication of bisindolylmaleimide with wortmannin or U0126 completely abolished the Zn 2þ -dependent phosphorylation of ERK1/2 or AKT, respectively ( Figure 4C and D) . These results indicate that PKC and cross talk between the MAPK and PI3K pathways are the major mediators of the Zn 2þ -dependent phosphorylation of ERK1/2 and AKT in prostate cancer cells.
The role of extracellular Zn 2þ -dependent signaling in prostate cell growth Because of the strong activation of MAPK and PI3K pathways by extracellular Zn 2þ , we asked if it accelerates cell growth. Prolonged Cit or with 10 mM citrate alone (Cit) for 60 min. Intracellular Ca 2þ was monitored and Zn 2þ (100 lM) was reapplied to the cells at the indicated time (arrow).
Extracellular zinc and zinc-citrate regulate growth and survival of prostate cancer cells exposure to Zn 2þ was shown previously to reduce prostate cell proliferation and induce cell death (32) . Yet, prolonged exposure is expected to induce desensitization of intracellular signaling (Figure 3) . We therefore employed a paradigm in which cells were only briefly exposed to Zn 2þ . This paradigm simulates more accurately the physiological environment in which most of the extracellular Zn 2þ is bound, though it may produce a brief rise in free Zn 2þ . To assess the effect of extracellular, Zn 2þ -dependent signaling on cell growth, PC-3 cells were treated daily for 10 min with Zn 2þ -containing (10 or 100 lM) Ringer's solution and cell number was monitored using sulphorhodamine B stain. Zn 2þ -dependent intracellular signaling was fully activated under these conditions (see insert in Figure 5A ), yet desensitization or Zn 2þ permeation was not apparent. To eliminate residual Zn 2þ , Ringer's solution containing the Zn 2þ chelator, CaED-TA (100 lM, 10 min), was used as an additional control. Cells were grown in serum-free medium to minimize the interference of Zn 2þ contamination or serum-derived growth factors. As shown in Figure  5A , the growth rate of cells treated with nominally Zn 2þ -free solution (control) or CaEDTA was attenuated. The brief daily exposure to 100 lM Zn 2þ enhanced PC-3 proliferation, already on the third day of treatment, by $30% compared with control cells (Figure 5A ). By the fifth day, the number of Zn 2þ -treated cells increased further and was 2-fold higher than the controls. The Zn 2þ -dependent enhancement of cell growth was dose dependent, as application of 10 lM Zn 2þ induced only about a 35% increase in cells by the fifth day.
To determine the effect of desensitization on Zn 2þ -dependent proliferation, PC-3 cells were treated daily with Zn 2þ Cit (using the same experimental paradigm described in Figure 3 ), followed by a short exposure to Zn 2þ (100 lM). Application of citrate alone (see Figure 3) served as a control. The number of control cells treated with citrate alone and then with Zn 2þ increased by 4-fold on the fifth day ( Figure 5B ). In contrast, pre-exposure of PC-3 cells to Zn 2þ Cit completely attenuated Zn 2þ -dependent cell growth ( Figure 5B ). In fact, the number of cells pretreated with Zn 2þ Cit decreased by the fifth day, similar to the effect of CaEDTA. These results indicate that extracellular Zn 2þ promotes cell growth suppressed by Zn 2þ Cit.
We next asked whether extracellular Zn 2þ also has a prosurvival effect. PC-3 cells were treated daily for 4 days with Zn 2þ , the Zn 2þ , and at the indicated times, cytosolic extracts were prepared and subjected to immunoblotting using phospho-ERK1/2 (p-ERK1/2) and total ERK (t-ERK) antibodies. Control cells were treated with CaEDTA (100 lM). Bottom: densitometry of pERK1/2 normalized to total ERK1/2 is shown as percentage of Zn 2þ -dependent activation. (B) Time dependence of AKT phosphorylation and densitometry monitored with phospho-AKT (p-AKT) and total AKT (t-AKT) antibodies using the paradigm described in A. (C) Zn 2þ was applied to PC-3 cells pretreated with the MEK1/2 inhibitor, U0126 (1 lM), Gaq inhibitor, YM-254890 (1 lM), the PKC inhibitor bisindolylmaleimide (BI) (2 nM), the PI3K inhibitor wortmannin (100 nM) or coapplication of bisindolylmaleimide (2 nM) and wortmannin (100 nM). Cytosolic extracts were subjected to p-ERK1/2 analysis as in A. (D) p-AKT analysis was performed on cells treated with the same inhibitors as in C or coapplication of bisindolylmaleimide (2 nM) and U0126 (1 lM).
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chelator CaEDTA or Ringer's solution (control) and subjected to trypan blue staining ( Figure 5C ). Brief daily exposure to Zn 2þ resulted in a significant reduction in the number of trypan blue stained (i.e. dead) cells. Zn 2þ chelation with CaEDTA resulted in a 10-fold increase in trypan blue staining compared with control cells. These results suggest that the effects of extracellular Zn 2þ on cell growth are also mediated by attenuation of cell death.
Zn 2þ -dependent enhancement of cell growth is not observed in prostate cancer cells which are deficient in ZnR activity Several sublines of PC-3 cells, differing in their metastatic potential and their response to chemotherapeutic drugs, have been described and attributed to their relatively high genetic instability and phenotypic drift (33, 34) . We therefore screened PC-3 lines from several sources, aiming to identify one not exhibiting Zn 2þ -dependent Ca 2þ release to further link Zn 2þ -induced intracellular signaling and prostate cancer cell growth. A comparison between the Ca 2þ rise triggered by extracellular Zn 2þ in our original PC-3 cells and a second subline is shown in Figure 6A . Application of 300 lM Zn 2þ to a subline, PC-3B, triggered a Ca 2þ rise with a rate that was only $10% of that observed in the original PC-3 cells. This attenuated Zn 2þ -dependent Ca 2þ rise suggests that PC-3B cells lack ZnR activity. To determine if the IP 3 pathway is functional in PC-3B cells, we tested if another Gq-protein-coupled receptor could trigger a Ca 2þ rise in these cells. A pronounced Ca 2þ rise was observed in the PC-3B cells following application of ATP (100 lM, Figure 6B ), which induces a purinergic response, indicating that the metabotropic pathway in these cells is intact. Both PC-3 and PC-3B cells express the cytokeratins 8/18 and neuron-specific enolase, which are commonly used as markers for this cell type [(33), data not shown]. These results indicate that PC-3 and PC-3B sublines differ in their ZnR activity, providing a useful experimental tool to address the specific role of this receptor in prostate cancer cells.
To determine the specific role of ZnR signaling in linking changes in extracellular Zn 2þ and the activation of MAPK and PI3K pathways, we compared the effects of extracellular Zn 2þ on ERK1/2 and AKT phosphorylation in the ZnR-deficient subline, PC-3B. Zn 2þ -dependent phosphorylation of ERK1/2 in the PC-3B subline was insignificant compared with control, untreated cells ( Figure 6C ) and much smaller than the Zn 2þ -dependent activation observed in the PC-3 cells ( Figure 4A ). Application of phorbol 12-myristate 13-acetate (250 nM), a known activator of MAPK in prostate cells (35) , resulted in a 10-fold increase in ERK1/2 phosphorylation in PC-3B cells, indicating that the MAPK pathway is functional in these cells. Basal phosphorylation of AKT in PC-3B cells, in the absence of Zn 2þ , was higher than in the PC-3 cells ( Figure 6C , note the left lane of the immunoblot as well as the scale of the densitometry as compared with Figure 4B ). No significant Zn 2þ -dependent phosphorylation of AKT was apparent, whereas ATP (100 lM) induced a rise in AKT phosphorylation by $7-fold, indicating the PI3K pathway is intact in the PC-3B cells. Thus, our results indicate that extracellular Zn 2þ -dependent activation of the MAPK and PI3K pathways is observed only in PC-3 cells exhibiting Zn 2þ -dependent metabotropic signaling. 
To assess the role of ZnR activity in enhancing cell growth, we compared cell proliferation in the PC-3B and PC-3 cells. The PC-3B cells exhibited a growth rate that was $2-fold slower than that of the PC-3 cells (control cells in Figures 5A and 6D, respectively) . In contrast to PC-3 cells, daily application of Zn 2þ to the PC-3B cells failed to significantly enhance cell growth over 5 days of treatment ( Figure 6D ). This suggests that Zn 2þ -dependent cell growth is apparent only in PC-3 cells which exhibit Zn 2þ -dependent metabotropic signaling.
Discussion
Prostate cancer is the second most common malignancy in men in Western countries and a major cause of death. While in the early stage, prostate cancer is treatable by hormones, the advanced stage is androgen insensitive and an effective therapeutic approach is still unavailable. Thus, novel molecular targets to facilitate treatment for this cancer are urgently sought. Among the most intriguing but less understood changes occurring in prostate cancer transformation is a 10-fold decrease in the concentration of Zn 2þ . In recent years, this ion has emerged as an important signaling agent, regulating downstream pathways involved in cell proliferation and survival (14, 36) . However, the signaling pathways activated by extracellular Zn 2þ in healthy and malignant prostate tissue remain unknown.
In the present work, we identified extracellular, Zn 2þ -dependent metabotropic Ca 2þ release in androgen-independent PC-3 and DU-145 prostate cancer cell lines and in the mouse prostate tumor TRAMP-1 cell line, but not in the androgen-sensitive LNCaP cells. Interestingly, the androgen-insensitive PC-3 cells exhibited two sublines that showed distinct ZnR activity. Our results, therefore, do not support a clear link between androgen sensitivity and extracellular Zn 2þ response. Previous work, however, has suggested that changes in androgen sensitivity of LNCap cells may be followed by changes in intracellular Zn 2þ , Zn 2þ -buffering proteins, such as Zn 2þ transporters and metallothioneins, as well as cell growth (37, 38) . This is consistent with other reports of decreased Zn 2þ permeability in androgeninsensitive cells and malignant tissue, linked to a reduced expression of ZIP1 (12, 39) . Additional studies are needed to determine if a link exists between Zn 2þ signaling, intracellular Zn 2þ concentration and androgen sensitivity.
In the present report, we have shown that extracellular Zn 2þ triggers the IP 3 pathway in PC-3 cells, leading to release of intracellular Ca 2þ . This Ca 2þ rise is mediated by a Gq-protein and activation of PLC and is abolished following depletion of TG-sensitive Ca 2þ stores. This subsequently leads to activation of MAPK and PI3K. This signaling pathway was previously attributed to a GPCR, termed ZnR (14, 22, 23) . Our data further indicate that a brief rise in extracellular Zn 2þ plays a role in promoting prostate cancer cell growth only in those cells exhibiting ZnR activity (i.e. PC-3 but not PC-3B cells). The results presented here indicate that prostate cancer cells are largely impermeable to Zn 2þ , in agreement with previous studies (2, 6, 12, 13) . Although the apparent K 0.5 of the prostate ZnR is 200 lM, our results indicate that Zn 2þ -dependent signaling in prostate cancer cells is activated, and induces enhanced proliferation, already at 10 lM. It is further important to note that even in the presence of citrate, Zn 2þ can trigger a ZnR response at slightly higher free Zn 2þ concentrations. Interestingly, Zn 2þ Cit complex led to functional desensitization of ZnR-mediated, intracellular Ca 2þ rise. Furthermore, Zn 2þ Cit-induced desensitization was followed by attenuation of Zn 2þ -dependent cell growth. The concentrations of both Zn 2þ and citrate used in our experiments are similar to those found in the non-neoplastic prostate, suggesting that ZnR is quiescent in the prostate tissue. One of the hallmarks of prostate cancer progression is a dramatic decrease in Zn 2þ and citrate concentrations that lower the buffer capacity for free Zn 2þ in the prostate (40) . Furthermore, because of the relatively low affinity of Zn 2þ to citrate, even a modest change in citrate concentration may dramatically alter the concentration of free Zn 2þ , thereby triggering a transient rise in Zn 2þ and activation of the Ca 2þ response. This suggests that a scenario in which ZnR is transiently activated in the prostate by a rise in extracellular Zn 2þ may also be considered. This further suggests that desensitization by Zn 2þ Cit plays an important role in suppressing tumor growth. The role of ZnR signaling would be expected to be more pronounced following metastasis of prostate tumor cells into peripheral tissues in which the extracellular Zn 2þ Cit concentration is negligible, minimizing ZnR desensitization. Several plausible mechanisms may trigger a transient rise in Zn 2þ concentration in the peripheral tissues. Among these, is the tissue destruction mediated by tumor invasion which can lead to release of Zn 2þ from injured cells. In addition, NO and oxidative signaling mediated by the tumor cells may induce release of Zn 2þ from metalloproteins (41) . Finally, in bone, arguably the most common and devastating target of prostate metastatic cells, the high concentrations of Zn 2þ released during bone destruction occurring in metastatic prostate cancer could potentially activate the ZnR (42) . Consistent with this hypothesis is the finding that ZnR activity was particularly intense in the metastatic prostate cancer cell lines. , 100 lM CaEDTA, or with Ringer's alone (control). Cell number was monitored using the sulphorhodamine B colorimetric assay during five consecutive days. For comparison, the effect of 100 lM Zn 2þ on cell number in the PC-3 cells is shown (same as in Figure 5A ).
Therefore, extracellular Zn 2þ signaling in prostate cancer represents an important pathway linking changes in Zn 2þ to prostate tumor cell growth and survival.
The identification of a PC-3 subline, PC-3B, that is deficient in extracellular Zn 2þ -dependent signaling, provides an important tool to assess the role of the Zn 2þ -dependent metabotropic response in prostate cancer. The spontaneous formation of PC-3 subline with distinct morphological and functional characteristics is common and is attributed to their genetic instability (33, 34) . It would be of interest to further characterize these sublines, for example, to determine if the difference in the response to extracellular Zn 2þ is also accompanied by a change in the expression pattern of other zinc transporters involved in prostate cancer (5, 12) .
The Zn 2þ Cit complex, at concentrations that did not trigger ZnR activity, induced a profound functional desensitization of the Zn 2þ -dependent activity. Desensitization by Zn 2þ Cit was similar to the desensitization induced by Zn 2þ alone, suggesting that the Zn 2þ Cit complex may allosterically interact with the ZnR. Although the molecular basis for this effect is still unknown, it is reminiscent of the constitutive desensitization encountered in other GPCRs (43) . For example, such desensitization, without prior activation of the intracellular signaling, has been attributed to activation of GPCR kinases. Constitutive desensitization has been also described for the serotonin receptor, 5-hydroxytryptamine (44), a member of the metabotropic glutamate receptor family.
The MAPK-and PI3K-signaling pathways participate in a wide variety of physiological processes and have been shown to induce proliferation of prostate cancer cells (29, 45) . The PI3K pathway is prominent in prostate cancer, where constitutively activated PI3K has been correlated with tumor cell survival (46) . Activation of PI3K has also been suggested to downregulate the androgen receptor, thereby inducing the shift toward advanced stages of this cancer (47) . Furthermore, PI3K activation was reported to induce chemoresistance of prostate cancer cells (48) . We have shown that the Zn 2þ -dependent MAPK and PI3K activation is correlated with enhancement of cell growth in PC-3 cells which exhibit ZnR activity. Our results indicate that extracellular Zn 2þ is inducing the activation of MAPK at least partially via a signaling pathway involving PI3 and PKC. A derivative of prostaglandin also activated this signaling pathway to trigger MAPK activation in PC-3 cells (49) . It was recently shown that MAPK activation is triggered by Zn 2þ in prostate cancer cells (13) ; this effect, however, was produced only after addition of a Zn 2þ ionophore. It is possible that in the presence of the ionophore, the activation of MAPK was also mediated via a distinct pathway. The ERK pathway has been linked to both proliferation and to attenuation of cell growth. While it was previously suggested that the rise in intracellular Zn 2þ , in the presence of the Zn 2þ ionophore, inhibited nuclear factor-kappa B activity and suppressed the invasiveness of PC-3 cells (13), our work indicates that extracellular Zn 2þ enhanced cell growth. These distinct effects of extracellular or intracellular Zn 2þ on cell fate are consistent with previous studies (36, 50, 51) . Activation of AKT by extracellular Zn 2þ via the ZnR was largely mediated by the IP 3 -dependent pathway, as the Gq and PKC inhibitors attenuated AKT phophorylation. Previous work has suggested that the Ca 2þ -independent PKCd is a major inhibitor of AKT which leads to apoptosis (52) . Our results, therefore, indicate that another isoenzyme of PKC is activated by extracellular Zn 2þ leading to cell survival. In support of this conclusion, the Ca 2þ -dependent PKCa was shown previously to activate ERK1/2 via transactivation by epidermal growth factor receptor in PC-3 cells (53) . The prolonged 3 h period that the phosphorylation of AKT persists following a short exposure to Zn 2þ underscores the role of Zn 2þ in activating signaling, leading to enhanced tumor cell growth. Finally, attenuation of the Zn 2þ -dependent phosphorylation of ERK1/2 by a PI3K inhibitor, and a similar effect of a MEK inhibitor on PI3K activation, indicate that these pathways interact to promote Zn 2þ -dependent cell proliferation, similar to the effect previously observed in Zn 2þ -dependent signaling in colon cells (14, 54) . Taken together, our results indicate that Zn 2þ activates several signaling pathways that interact to enhance tumor progression. The lack of a Zn 2þ -dependent phosphorylation of the MAPK and PI3K in ZnR-deficient, PC-3B cells, indicates that activation of both pathways is primarily mediated by the ZnR.
In conclusion, our results show that extracellular Zn 2þ acts as a signaling agent via the ZnR in prostate cancer cells. Our results further identify a unique role for Zn 2þ Cit as an effective suppressor of extracellular Zn 2þ signaling. The finding that a rise in extracellular Zn 2þ significantly enhances prostate cancer cell proliferation and survival suggests that blocking extracellular Zn 2þ signaling can be a safe and effective therapeutic strategy to attenuate prostate cancer cell growth and tumor progression.
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